BioNTech Launches Breast Cancer Diagnostic Test in EU
BioNTech AG has launched its first product, the MammaTyper breast cancer diagnostic test for use in pathology laboratories, in EU markets, the German devicemaker announced Thursday.
The test uses RNA analysis to provide precise gene expression measurements, offering molecular subtyping of the cancerous tissue.
The in vitro diagnostic enables detection of four biomarkers indicative of breast cancer tumors and features same-day results rendering.
The MammaTyper can be used in conjunction with the devicemaker’s RNXtract RNA extraction kit which will also launch this year. — Jason Scott